CSBR · Champions Oncology Inc. Common Stock
View on chartInsiders & Stakes
| Joel Ackerman Director | ▲ Buy | Option Exercise | 1,056,539 Shares held | 10/30/2025 | View profile |
| Morris Ronnie CEO | ▲ Buy | Open Market | 858,878 Shares held | 3/17/2023 | View profile |
| SIDRANSKY DAVID Director | ▼ Sell | Tax Withholding | 767,043 Shares held | 10/12/2022 | View profile |
| Mendelson Daniel Newman Director | ▲ Buy | Open Market | 198,625 Shares held | 1/12/2024 | View profile |
| Scott R. Tobin 10% Owner | ▲ Buy | Option Exercise | 30,000 Shares held | 10/12/2022 | View profile |
| Breitfeld Philip P. Director | ▼ Sell | Other | 5,717 Shares held | 3/25/2025 | View profile |
Transaction History
| Joel Ackerman | ▲ Buy | Option Exercise | 94,405 | $198K | 10/30/2025 |
| Breitfeld Philip P. | ▼ Sell | Other | 4,150 | $0 | 3/25/2025 |
| Joel Ackerman | ▲ Buy | Option Exercise | 16,667 | $91K | 10/31/2024 |
| Joel Ackerman | ▲ Buy | Option Exercise | 88,470 | $186K | 10/31/2024 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 1,000 | $7K | 1/12/2024 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 2,000 | $13K | 1/11/2024 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 2,944 | $19K | 1/10/2024 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 3,000 | $19K | 1/9/2024 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 1,000 | $6K | 1/8/2024 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 2,000 | $12K | 1/5/2024 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 3,000 | $18K | 1/4/2024 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 500 | $3K | 1/3/2024 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 2,500 | $12K | 12/21/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 2,100 | $10K | 12/20/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 5,000 | $24K | 12/19/2023 |
| Joel Ackerman | ▲ Buy | Option Exercise | 114,552 | $241K | 10/17/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 5,000 | $32K | 10/11/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 1,100 | $7K | 10/10/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 1,530 | $10K | 10/6/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 2,000 | $13K | 10/5/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 5,000 | $32K | 10/4/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 2,500 | $16K | 10/3/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 4,000 | $25K | 9/29/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 5,000 | $31K | 9/28/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 1,500 | $9K | 9/27/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 5,000 | $28K | 9/26/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 3,812 | $21K | 9/22/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 5,000 | $28K | 9/21/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 4,018 | $22K | 9/20/2023 |
| Mendelson Daniel Newman | ▲ Buy | Open Market | 5,000 | $26K | 9/19/2023 |
| Morris Ronnie | ▲ Buy | Open Market | 12,382 | $50K | 3/17/2023 |
| Joel Ackerman | ▲ Buy | Option Exercise | 16,667 | $54K | 10/19/2022 |
| SIDRANSKY DAVID | ▲ Buy | Option Exercise | 8,333 | $27K | 10/12/2022 |
| SIDRANSKY DAVID | ▼ Sell | Tax Withholding | 3,562 | $27K | 10/12/2022 |
| Breitfeld Philip P. | ▲ Buy | Option Exercise | 8,333 | $27K | 10/12/2022 |
| Breitfeld Philip P. | ▼ Sell | Tax Withholding | 3,562 | $27K | 10/12/2022 |
| Scott R. Tobin | ▲ Buy | Option Exercise | 10,000 | $32K | 10/12/2022 |
| SIDRANSKY DAVID | ▲ Buy | Option Exercise | 16,667 | $27K | 10/15/2021 |
| SIDRANSKY DAVID | ▼ Sell | Tax Withholding | 2,629 | $27K | 10/15/2021 |
| Scott R. Tobin | ▲ Buy | Option Exercise | 10,000 | $16K | 10/12/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Champions Oncology Highlighted in Global PDX Models Shift
Champions Oncology was highlighted in a Yahoo article that discusses the shift toward patient‑derived xenograft (PDX) models in precision oncology. The story compares the company with peers like Charles River, Crown Bioscience, The Jackson Laboratory and Oncodesign, indicating growing industry focus on PDX‑based research. This comparison suggests Champions may benefit from increased demand for its precision oncology solutions. No new financial data were disclosed.
Champions Oncology Highlighted in Global PDX Models Shift. Champions Oncology was highlighted in a Yahoo article that discusses the shift toward patient‑derived xenograft (PDX) models in precision oncology. The story compares the company with peers like Charles River, Crown Bioscience, The Jackson Laboratory and Oncodesign, indicating growing industry focus on PDX‑based research. This comparison suggests Champions may benefit from increased demand for its precision oncology solutions. No new financial data were disclosed.